Evidence map›Paper›PMID 40711525›Full record

SynthesisAnnals of hematology2025

Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials.

Shira Buchrits, Gal Trieman, Odil Giladi, Liron Hofstetter, Ronit Gurion, Galit Granot, Adi Shacham-Abulafia, Pia Raanani, Anat Gafter-Gvili

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shira BuchritsInstitute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel. shirab2805@gmail.com.
Gal TriemanInternal Medicine Department A, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
Odil GiladiInstitute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.
Liron HofstetterInstitute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.
Ronit GurionInstitute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.
Galit GranotInstitute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.
Adi Shacham-AbulafiaInstitute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.
Pia RaananiInstitute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.
Anat Gafter-GviliInstitute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of Bruton Tyrosine Kinase inhibitors (BTKis) has revolutionized the management of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, increased infection rates have been reported in patients receiving BTKis in multiple clinical trials. This study aimed to evaluate the risk of infections associated with BTKis compared to other therapeutic regimens in CLL/SLL patients. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. We included trials comparing BTKi-containing regimens (e.g., BTKi alone or combined with anti-CD20 or venetoclax) to other therapeutic regimens, as well as studies comparing different BTKis or BTKi combinations. Primary outcomes were the risk of any infection and grade 3-4 infections. Secondary outcomes included pneumonia, sepsis, septic shock, COVID-19, fungal infections, fatal infections, bacteremia, and febrile neutropenia. Pooled risk ratios (RR) with 95% confidence intervals (CIs) were estimated using fixed or random effects models based on heterogeneity. Eighteen trials encompassing 8,324 patients were included. BTKi-containing regimens, either as monotherapy or combined with anti-CD20 or venetoclax, were not associated with a significantly increased risk of any infection compared to other regimens [BTKi + anti-CD20 or venetoclax: RR 0.93 (95% CI: 0.79-1.09, I

Indexed as

Agammaglobulinaemia Tyrosine KinaseInfectionsLeukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicCOVID-19HumansRandomized Controlled Trials as TopicSulfonamidesTyrosine Kinase InhibitorsAgammaglobulinaemia Tyrosine KinaseBridged Bicyclo Compounds, HeterocyclicBTK protein, humanProtein Kinase InhibitorsSulfonamidesTyrosine Kinase InhibitorsvenetoclaxBruton tyrosine kinase inhibitorsBTK inhibitor toxicityChronic lymphocytic leukaemia (CLL)

Identifiers

PMID40711525
PMCPMC12432036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.